NCT02979665View on ClinicalTrials.gov

Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema

CompletedOBSERVATIONAL
Enrollment

51

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Diabetic Macular Edema
Interventions
DRUG

Ranibizumab Ophthalmic

"Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the wet type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss and diabetic macular edema (DME)."

All Listed Sponsors
lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT02979665 - Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema | Biotech Hunter | Biotech Hunter